- Home
- CRBP vs NUAI Comparison
CRBP vs NUAI Comparison
Compare CRBP & NUAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRBP
- NUAI
- Stock Information
- Founded
- CRBP 2009
- NUAI N/A
- Country
- CRBP United States
- NUAI United States
- Employees
- CRBP N/A
- NUAI N/A
- Industry
- CRBP Biotechnology: Pharmaceutical Preparations
- NUAI Oil & Gas Production
- Sector
- CRBP Health Care
- NUAI Energy
- Exchange
- CRBP Nasdaq
- NUAI Nasdaq
- Market Cap
- CRBP 210.8M
- NUAI 203.1M
- IPO Year
- CRBP N/A
- NUAI N/A
- Fundamental
- Price
- CRBP $11.23
- NUAI $4.62
- Analyst Decision
- CRBP Strong Buy
- NUAI
- Analyst Count
- CRBP 9
- NUAI 0
- Target Price
- CRBP $48.38
- NUAI N/A
- AVG Volume (30 Days)
- CRBP 546.2K
- NUAI 11.2M
- Earning Date
- CRBP 11-12-2025
- NUAI 11-13-2025
- Dividend Yield
- CRBP N/A
- NUAI N/A
- EPS Growth
- CRBP N/A
- NUAI N/A
- EPS
- CRBP N/A
- NUAI N/A
- Revenue
- CRBP N/A
- NUAI $843,029.00
- Revenue This Year
- CRBP N/A
- NUAI N/A
- Revenue Next Year
- CRBP $220.00
- NUAI N/A
- P/E Ratio
- CRBP N/A
- NUAI N/A
- Revenue Growth
- CRBP N/A
- NUAI 50.89
- 52 Week Low
- CRBP $4.64
- NUAI $0.32
- 52 Week High
- CRBP $20.56
- NUAI $12.29
- Technical
- Relative Strength Index (RSI)
- CRBP 38.90
- NUAI 53.14
- Support Level
- CRBP $10.88
- NUAI $3.23
- Resistance Level
- CRBP $12.43
- NUAI $4.50
- Average True Range (ATR)
- CRBP 0.76
- NUAI 0.80
- MACD
- CRBP 0.05
- NUAI -0.17
- Stochastic Oscillator
- CRBP 51.59
- NUAI 36.54
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
About NUAI New Era Energy & Digital Inc. Common Stock
New Era Energy & Digital Inc is engaged into a fully integrated energy supplier delivering next-gen digital infrastructure and power assets. The company provides turnkey solutions to speed up data center deployment and reduce costs. The company focuses on future-proofing infrastructure for hyperscale, enterprise, and edge operators. The company provide integrated energy and digital solutions to support accelerating AI infrastructure deployment and optimize data center investments.